Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

President Biden’s single term in office will be marked by several moments that saw the White House take the spotlight. It began with the pandemic and a raucous State of the Union. Then there was

Abe Sutton, a health policy aide in the first Trump administration, is likely to be named head of the Center for Medicare and Medicaid Innovation at CMS.

Biden’s domestic policy adviser says Trump avoided pledges to overhaul the Affordable Care Act and other health programs — but changes are coming anyway.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden leaving 11th-hour health measures for TrumpThe Biden administration in its final days has been

Biden spent like no president in history, and, with a sleight of hand, by taking hundreds of billions out of Medicare and spending it on green energy subsidies.

Health policy experts Chris Klomp, Stephanie Carlton and Abe Sutton appear favored for senior roles in the emerging Trump administration.

The Centers for Medicare & Medicaid Services wants to lower the cost for 15 more drugs including Ozempic and Wegovy.

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.

President-elect Donald Trump's inauguration comes at a pivotal time in American history. Insulated from controversy, Trump will enter the White House more prepared than when he first won in 2016.